FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma
Sep 25
2019
The Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).
